The AELIX-002 study aims to evaluate the safety and the immunogenicity of DNA.HTI administered alone and as part of an heterologous prime-boost regimen in combination with MVA.HTI in early diagnosed and treated HIV-1 positive individuals, males and females,18-50 years of age.